October 14, 2019
Susan G. Komen® Urges Commitment to Conquer Metastatic Breast Cancers
Komen vows to drive breakthroughs for the most-deadly breast cancers and educate those who believe breast cancers are easily treated…
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
October 14, 2019
Exicure to Present Clinical Results from XCUR17 at the 15th Annual Meeting of the Oligonucleotide Therapeutics Society
CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DigitalDrugDesign–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid…
October 14, 2019
Excellere Portfolio Company, Biocare Medical, Appoints Nicolas Barthelemy as Executive Chairman
PACHECO, Calif.–(BUSINESS WIRE)–Biocare Medical (“Biocare”), a leading developer of world-class immunohistochemistry (“IHC”) and molecular reagents and instrumentation, announced today the…
October 14, 2019
Phase III PEMPHIX Study Shows Genentech’s Rituxan (rituximab) Superior to Mycophenolate Mofetil in Patients With Pemphigus Vulgaris
Genentech’s study reinforces efficacy and safety of Rituxan for treatment of PV, a rare autoimmune condition characterized by blistering of the skin and mucous membranes, showing that 40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with Rituxan compared to 9.5% of patients on mycophenolate mofetil.
October 14, 2019
Mogrify raises additional $16M, (total $20M) in series A funding
Mogrify has raised additional $16 million to advance its mission to transform the development of life-saving cell therapies, with initial…
October 14, 2019
Abzena Names Kimball Hall as Chief Operating Officer
SAN DIEGO, Calif.–(BUSINESS WIRE)–Abzena announced today the appointment of Kimball Hall as Chief Operating Officer, adding to the company’s executive…
October 14, 2019
Novigenix and RadioMedix set to work on neuroendocrine cancer precision diagnostic test
Novigenix and RadioMEdix have announced collaboration on developing a test to measure response to radiopharmaceutical therapy, based on Novigenix’s technology.
October 14, 2019
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.
CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™…
October 14, 2019
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the U.S.
CEQUA™ (cyclosporine ophthalmic solution) 0.09% for topical ophthalmic use is the first and only approved cyclosporine treatment delivered with NCELL™…
October 13, 2019
Pfizer’s abrocitinib met all endpoints in moderate to severe atopic dermatitis study
Pfizer has presented positive phase 3 data at the 28th Congress of the European Academy of Dermatology and Venereology for abrocitinib in moderate to severe atopic dermatitis, in which abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study.